Navigation Links
Asymmetrex’s Plan for Free Stem Cell Counting Is The Feature Story by Superb Crew News
Date:6/23/2020

In its June 22 online post, business and technology news platform Superb Crew reported its feature interview with Dr. James L. Sherley, M.D., Ph.D., founder and director of stem cell biotechnology company Asymmetrex. Superb Crew decided to highlight Asymmetrex after the company announced on June 16 that starting July 5 it would begin offering free tissue stem cell counting at its company website.

In the interview, Sherley discussed Asymmetrex’s tissue stem cell counting technology with the perspective that it is a very recent development for the industry. He noted that, like many new transformative biotechnologies, it and its value are not yet widely known. The planned free stem cell counting site is a part of Asymmetrex’s greater vision to increase academic and industry awareness of the need for tissue stem cell counting and its value, while at the same time making it readily available for immediate practice.

An earlier podcast series on “Counting Stem Cells” featured on the international stem cell industry networking platform RegMedNet, relates the many benefits of Asymmetrex’s technology for stem cell research, stem cell medicine, tissue stem cell biomanufacturing, pharmaceutical development, and environmental health science. By getting the technology out into use for free, Asymmetrex plans to “ignite a widespread adoption of tissue stem cell counting as [the] new normal” for tissue stem cell research, stem cell medicine, and drug development.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Asymmetrex markets the first technology for determination of the dosage and quality of tissue stem cell preparations (the “AlphaSTEM Test™”) for use in stem cell transplantation therapies, cell biomanufacturing, and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute BioFabUSA and the Massachusetts Biotechnology Council.

Read the full story at https://www.prweb.com/releases/asymmetrexs_plan_for_free_stem_cell_counting_is_the_feature_story_by_superb_crew_news/prweb17210121.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology news :

1. Counting the invisible by sound -- a new approach to estimate seabird populations
2. Counting down to FEBS-EMBO 2014 in Paris, France
3. Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation
4. Asymmetrex Presents Proposal for ASTM Interlaboratory Evaluation of AlphaSTEM Test™ Technology Towards Establishing A Standard for Counting Therapeutic Stem Cells
5. Asymmetrex Approved to Conduct an ASTM Interlaboratory Evaluation of Its AlphaSTEM Test™ Technology as a Standard for Counting Therapeutic Adult Tissue Stem Cells
6. Asymmetrex Announces New Algorithms for Rapid Low Cost Counting of Therapeutic Tissue Stem Cells
7. Asymmetrex Announces Plans to Provide Free Tissue Stem Cell Counting
8. Geosphere features top geoscience technology, including LiDAR, EarthScope, CHIRP, ALSM, and IODP
9. Medbox Featured in Bloomberg Businessweek
10. Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system
11. Fluke Biomedical launches portable, feature-rich ProSim 3 and 2 Vital Signs Simulators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2020)... ... August 25, 2020 , ... Catalent, ... drugs, biologics, cell and gene therapies, and consumer health products, today announced that ... Virtual Conference & Expo, taking place between Aug. 31 – September 4, 2020. ...
(Date:8/21/2020)... ... 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company ... Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for ... Approval of this IND allows Sentien to initiate a Phase 1/2 study with ...
(Date:8/21/2020)... Rochelle, Virginia (PRWEB) , ... August 20, 2020 ... ... announced today that Hassan Movahhed , a Clinical Operations executive with expertise ... CRO management, has joined the firm as an Expert Consultant. Throughout his career, ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... , ... August 11, 2020 , ... ... year to expand the Facioscapulohumeral Muscular Dystrophy Clinical Trial Research Network ... and 2022. The network is a consortium of academic research centers in the ...
(Date:8/3/2020)... ... August 03, 2020 , ... ... announced Jim Corrigan, President and CEO has been named one of the 100 ... of industry sectors, PharmaVoice 100 honorees are selected based on how they have ...
(Date:7/31/2020)... Mass. (PRWEB) , ... July 29, 2020 , ... ... highly reliable, solid-state radar transmitter systems that can be configured to drive Klystrons, ... single controller that can drive one or two switches in a push-pull configuration; ...
(Date:7/31/2020)... MIAMI (PRWEB) , ... July 29, 2020 , ... ... nearly 200 of the top radiation centers in 16 countries, has reached its ... years, SDX® is now in routine use at top universities including University of ...
Breaking Biology Technology: